Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors

Conditions:   Solid Tumors, Adult;   Solid Tumor;   Mesothelioma (MPM);   Epithelioid Hemangioendothelioma (EHE);   NF2 Deficient Mesothelioma;   Other NF2 Deficient Solid Tumors and Solid Tumors With YAP1/TAZ Fusion Genes;   NF2 Deficiency;   YAP1 or TAZ Gene Fusions Intervention:   Drug: IK-930 Sponsor:   Ikena Oncology Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials